Bringing Hope to Patients Through Science and Innovation
In 2000, Oncopeptides AB (publ) was founded by leading Swedish scientists to develop therapies for difficult-to-treat hematological diseases. Since that time, Oncopeptides has developed a proprietary Peptide-Drug Conjugate (PDC) Platform. Peptide-drug conjugates leverage aminopeptidases and release alkylating agents rapidly into tumor cells. Aminopeptidases are overexpressed in tumor cells and are even more pronounced in advanced cancers and tumors with a high mutational burden. Thus, leveraging aminopeptidases results in selective activity in cancer cells.On February 28, 2021, the U.S. Food and Drug Administration (FDA) approved PEPAXTO® (melphalan flufenamide), the first commercial product from the PDC platform.
Commitment to Patients
Oncopeptides has established a Patient Assistance Program called ON COURSE for people who may not have access to health insurance or have an insurance plan that does not cover the entire cost of the medication. Some restrictions apply and patients need to meet certain eligibility criteria. Additionally, the ON COURSE team offers benefits verification, prior authorization assistance, claims management and help with appeals. The ON COURSE team is comprised of nurse case managers that offer personalized attention through the treatment process including helping patients and caregivers connect to support groups and organizations in the multiple myeloma community. To learn more, please visit www.ONCOURSEsupport.com.
Oncopeptides has also informed the European Medicines Agency (EMA) about its intention to submit an application for a conditional marketing authorization of melphalan flufenamide in the European Union. The FDA and EMA submissions are based upon the results from the pivotal phase 2 study HORIZON, evaluating intravenous melphalan flufenamide in combination with dexamethasone in patients with relapsed refractory multiple myeloma (RRMM).
In October 2020, Oncopeptides submitted an Investigational New Drug (IND) application to the FDA for OPD5, a second drug candidate based on the proprietary Peptide Drug Conjugate platform (PDC). Oncopeptides estimates that it will start the first clinical study with OPD5 in the first half of 2021.
Join Our Growing Team
This is an exciting time to join the Oncopeptides’ Team. Oncopeptides is actively seeking bright, passionate candidates with health care or biopharmaceutical experience. Learn more and submit your resume by visiting our Careers page.
Oncopeptides’ headquarters is in Stockholm, Sweden with a U.S. headquarters in Waltham, MA, outside of Boston. Oncopeptides also has a footprint in the San Francisco area, with an office in Los Altos, California.